Novavax
Europe to pay less than US for Pfizer COVID-19 vaccine
The European Union has struck a deal to initially pay less for Pfizer’s COVID-19 vaccine candidate than the United States, an EU official told Reuters News Agency as the bloc announced on Wednesday it had secured an agreement for up to 300 million doses. The experimental drug, developed in conjunction with Germany’s BioNTech, is the frontrunner in a global race to produce a vaccine, with interim data released on Monday showing it was more than 90 percent effective at protecting people from COVID-19 in a large-scale clinical trial. Under the EU deal, 27 European countries could buy 200 million doses, and have an option to buy another 100 million. The bloc will pay less than $19.50 per jab, a senior EU official involved in talks with vaccine makers told Reuters, adding that partly reflected ...
Britain secures early access to promising vaccine candidates
The British government on Friday announced that it had secured early access to 90 million doses of two new promising vaccine candidates. British citizens will receive early access to 90 million doses of the two COVID-19 vaccine candidates should they prove safe and effective. By far, the British government has secured access to six different vaccine candidates as part of the government’s strategy to build a portfolio of promising new vaccines should any be found to be safe and effective. The government has also agreed in principle to co-fund a global clinical trial with the Janssen Pharmaceutical Companies of Johnson and Johnson to establish how effective their vaccine could be in providing long-term immunity against COVID-19. The next phase of Janssen’s clinical trials is expected to begi...
